These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12907021)

  • 21. Are new drugs for schizophrenia better than old ones?
    Anghelescu I; Dettling M
    Lancet; 2009 Apr; 373(9671):1249; author reply 1249-50. PubMed ID: 19362668
    [No Abstract]   [Full Text] [Related]  

  • 22. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are new drugs for schizophrenia better than old ones?
    Jauhar S;
    Lancet; 2009 Apr; 373(9671):1249; author reply 1249-50. PubMed ID: 19362669
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
    Fusar-Poli P; Kempton MJ; Rosenheck RA
    Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine.
    Sherwood M; Thornton AE; Honer WG
    J Psychopharmacol; 2012 Sep; 26(9):1175-84. PubMed ID: 22465946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Maintenance therapy in schizophrenia -- a brief review of the literature].
    Balla P; Frecska E
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):197-200. PubMed ID: 22987733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
    Pecenak J
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.
    Ezewuzie N; Taylor D
    J Psychopharmacol; 2006 Jan; 20(1):86-90. PubMed ID: 16174679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CATIE study.
    Basil B; Mathews M; Adetunji B; Budur K
    Am J Psychiatry; 2006 Mar; 163(3):555; author reply 555-6. PubMed ID: 16513895
    [No Abstract]   [Full Text] [Related]  

  • 31. New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence.
    Jakovljević M
    Psychiatr Danub; 2009 Dec; 21(4):446-52. PubMed ID: 19935477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophrenia.
    Lee J; Remington G
    Am J Psychiatry; 2014 Jan; 171(1):118-9. PubMed ID: 24399431
    [No Abstract]   [Full Text] [Related]  

  • 33. A Bayesian framework to account for uncertainty due to missing binary outcome data in pairwise meta-analysis.
    Turner NL; Dias S; Ades AE; Welton NJ
    Stat Med; 2015 May; 34(12):2062-80. PubMed ID: 25809313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The spurious advance of antipsychotic drug therapy.
    Tyrer P; Kendall T
    Lancet; 2009 Jan; 373(9657):4-5. PubMed ID: 19058841
    [No Abstract]   [Full Text] [Related]  

  • 35. Old versus new: weighing the evidence between the first- and second-generation antipsychotics.
    Davis JM; Chen N
    Eur Psychiatry; 2005 Jan; 20(1):7-14. PubMed ID: 15642438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes similar with first- and second-generation antipsychotics.
    Seidlinger J; Provost GP
    Am J Health Syst Pharm; 2006 Nov; 63(22):2172, 2175. PubMed ID: 17090731
    [No Abstract]   [Full Text] [Related]  

  • 37. Relapse with oral antipsychotics versus long-acting injectable antipsychotics: new paradoxical findings.
    Jobe TH; Harrow M
    Evid Based Ment Health; 2014 Aug; 17(3):84. PubMed ID: 25043434
    [No Abstract]   [Full Text] [Related]  

  • 38. Ranking Antipsychotics for Efficacy and Safety in Schizophrenia.
    Correll CU; Kane JM
    JAMA Psychiatry; 2020 Mar; 77(3):225-226. PubMed ID: 31693073
    [No Abstract]   [Full Text] [Related]  

  • 39. Is there rebound psychosis on withdrawal of antipsychotic medication in schizophrenia?
    Taylor MJ; Yim S
    Schizophr Res; 2018 Nov; 201():430-431. PubMed ID: 29887253
    [No Abstract]   [Full Text] [Related]  

  • 40. [Current assessment of new/atypical neuroleptic agents].
    Möller HJ
    Nervenarzt; 2000 May; 71(5):329-44. PubMed ID: 10846708
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.